Physiomics PLC (PYSM)

London
6.500
-0.100(-1.51%)
  • Volume:
    931,947
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    6.500 - 6.500

PYSM Overview

Prev. Close
6.6
Day's Range
6.5-6.5
Revenue
700K
Open
6.6
52 wk Range
5.06-10.65
EPS
0
Volume
931,947
Market Cap
6.33M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
640,123
P/E Ratio
-
Beta
-2.25
1-Year Change
-5.04%
Shares Outstanding
97,334,778
Next Earnings Date
02 Mar 2022
What is your sentiment on Physiomics PLC?
or
Market is currently closed. Voting is open during market hours.

Physiomics PLC News

  • Physiomics rises early after contract awards
    • ByProactiveinvestors-

    Physiomics PLC (LON:PYC) was an early riser on Friday, adding 8% to 6.55p after being awarded two further contracts by existing client Bicycle Therapeutics. The projects, to be...

  • Physiomics falls after a profit warning
    • ByProactiveinvestors-

    Physiomics PLC (LON:PYC) retreated 7.0% to 5.95p after a poorly-received trading update that included a profit warning. The provider of technology-based solutions to predict the...

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong BuyStrong BuyStrong BuySell
Technical IndicatorsStrong BuyBuyStrong BuyStrong BuyStrong Sell
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Sell

Physiomics PLC Company Profile

Physiomics PLC Company Profile

Employees
7

Physiomics Plc is engaged in the provision of outsourced systems and computational biology services to pharmaceutical companies. The Company is focused on the development of Virtual Tumour Clinical, to directly predict optimal regimens for human clinical trials; Cardiac tox prediction service, to predict unwanted toxic side effects of drug candidates in the drug discovery process, and Drug combinations database, for researchers and clinicians to access literature data on pre-clinical and clinical regimens and their effects. Its services include Target Validation, Mechanism of Action Studies, Lead Selection, Clinical Pharmacokinetic/Pharmacodynamics (PK/PD), EASYAP/Cardiac Toxicity Service, Virtual Tumour Preclinical and Virtual Tumour Clinical. It offers a services and technology for predicting cardiac toxicity. It also focuses on offering offer Model Based Drug Development (MBDD) services, which include Population PKPD analysis of clinical data and Back-translational analysis.

Read More
  • got to crack that 7.30 to stay above the daily moving averages this must be it's multi attempt
    0
    • what's with the volatility today?
      0
      • 8.18p
        0
        • Been in this for 4 years, seen 30p topping up at 5p. lots of good work 👏
          0
          • shares outstanding is incorrect, showing incorrect market value.
            1
            • follow the trend, target 12.5p. easy
              1
              • follow the trent. target 12.5p. easy
                0
                • back to 8.5p
                  0
                  • just went to 17p in 8 minutes
                    0
                    • Feel sorry for those who bouht at 16
                      0
                  • 14p
                    0
                    • 8.8p market cap 8m
                      0
                      • +150%
                        0
                        • GSK news expected this week!
                          1
                          • what year?
                            0
                        • if they get a deal with GSK this could be big for PYSM... #pyc
                          5
                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.